Leveraging Evolving Data to Inform Treatment in HR-Positive, HER2-Negative Advanced Breast Cancer

Download All
Watch the interactive on-demand Webcast and download the slides from a CCO symposium at SABCS 2019 to get up to date on the latest clinical data informing optimal treatment of HR+/HER2- MBC, including expert discussion of patient cases and a look ahead at promising agents in the setting of endocrine therapy–pretreated disease that may soon change practice.
Joyce O'Shaughnessy, MD
Program Director
Hope S. Rugo, MD
Eric P. Winer, MD

Downloadable Slidesets

Download this slideset to explore future directions in the treatment of HR+/HER2- metastatic breast cancer, including a review of novel agents in the setting of resistance to standard-of-care therapies.

Joyce O'Shaughnessy, MD
Program Director
Released: December 11, 2019

Download this slideset to review the latest clinical data on the evolving role of mTOR and PIK3 inhibitors in the treatment of HR+/HER2- metastatic breast cancer.

Hope S. Rugo, MD Released: December 11, 2019

Download this slideset to review the latest clinical data informing optimal use of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer, including an overview of resistance to these agents.

Eric P. Winer, MD Released: December 11, 2019
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Immunomedics, Inc.
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue